23948sdkhjf
Logga in eller skapa för att spara artiklar
Få tillgång till allt innehåll på Life Science Sweden
Ingen bindningstid eller kortinformation krävs
Gäller endast personlig prenumeration.
Kontakta oss för en företagslösning.

Italian pharmaceutical company buys rights to immunotherapy from Sanofi

Italy's Recordati buys the rights to a treatment for the rare autoimmune disease cold agglutinin disease (CAD).

Enjaymo (sutimlimab) is a biologic drug that is the only approved treatment for cold agglutinin disease. On Friday, Recordati announced that the company is acquiring the global rights for the drug from France's Sanofi for 825 million US dollars.

– This transaction is in-line with our broader strategy, reaffirms our commitment to the Rare Diseases space and is complementary to our oncology portfolio, says Rob Koremans, Chief Executive Officer of Recordati, in a press release.

Recordati, headquartered in Milan, Italy, is present in 150 countries. At the end of 2023, the company had 4,450 employees and had consolidated revenue of € 2,082.3 million.

News in English Se tema
BREAKING
{{ article.headline }}
0.085